TD2 and Deep Lens Partner to Enable Diversity, Access and Faster Clinical Trial Enrollment for Community-Based Oncology Practices

Key Partnership to Connect Patients to Precision Oncology Clinical Trials and New Therapies, Accelerating Access to Promising Treatments

SCOTTSDALE, Arizona, September 16, 2021– (BUSINESS WIRE) – Translational Drug Development (TD2), a leading precision oncology contract research organization (CRO), and Deep Lens have announced a strategic partnership that will improve access to oncology treatments at measurement and new clinical studies for patients receiving care in community-based oncology practices. The partnership will allow TD2 to deliver Deep Lens’s proprietary clinical trial matchmaking solution, VIPER ™, along with other research coordination services, to its drug development clients, improving hospital capacity. , trial coordinators, investigators and patients to promote, collaborate, participate and manage clinical trials in oncology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005481/en/

There has been tremendous growth in precision oncology, or the development of treatments that target the molecular profile of a patient’s tumor. The number of new approved immunotherapies and agents targeted for different cancer indications has increased dramatically over the past five years, as has the number of clinical trials investigating their safety and efficacy.1. However, identifying and recruiting eligible patients for precision medicine trials can be difficult. Complex eligibility criteria coupled with very tight registration deadlines can be difficult and labor intensive for study sites and sponsors. Mixing TD2’s Precision Oncology Expertise with Deep Lens Clinical Trial Matching Solution Platform will improve trial enrollment and enrollment efficiency, increase patient access to trials , particularly at community oncology sites, where the majority of patients are diagnosed, and will facilitate improved access to the right care, for the right patient, at the right time.

The Deep Lens VIPER platform automates the study selection process from patient diagnosis to qualified enrollment, including ingestion of genomic, EMR, pathology, radiology and other data on the patients. VIPER provides rich data and interactive reporting capabilities to aggregate patient data at the site and study level, making it easier for sites to meet study goals.

“The top priority for TD2 is to ensure that every patient who participates in a TD2 clinical trial has the opportunity to achieve clinical benefit,” said Stephen Gately, President and CEO of TD2. “By working with the Deep Lens platform and coordinators, TD2 can match the results of cutting-edge scientific and molecular testing with the inclusion / exclusion criteria of clinical protocols to ensure patients have access to clinical trials where it is needed. there is an increased probability of profit. We are truly excited that this partnership has the potential to change the way early phase oncology trials are conducted and enrolled, taking the pressure off sites to find the next patient and focusing on the right patient. “

“The process of drug development has broadened dramatically as our knowledge and understanding of cancer has evolved, resulting in an increase in the number of precision medicine trials studying targeted therapies. While this is a positive step in our fight against cancer, unfortunately the vast majority of these trials fail to recruit enough patients to progress, ”said Dave Billiter, co-founder and CEO by Deep Lens. “Our approach is to reach more patients by working in community oncology, where the majority of these patients are diagnosed and treated. The partnership with TD2 will allow us to help drug developers identify and enroll patients in trials for which they are eligible. – thanks to our AI-based platform, we can do this at the time of a patient’s diagnosis. This means more patients have faster access to life-changing therapies and drug developers can more effectively test the safety and effectiveness of new therapies in more diverse populations. “

About TD2

TD2 is a leader in precision oncology, providing innovative services for better drug development. With a team of dedicated experts with extensive experience and understanding of cancer medicine, TD2 is uniquely positioned to support the accelerated development of new therapies. Rigorous, high-throughput preclinical translational development services, combined with regulatory affairs expertise, enable the design and execution of clinical trials to be personalized. The wide range of capabilities encourages the rapid selection of patient populations most likely to benefit from a new agent and the rapid identification of clinically significant parameters. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process with the ultimate goal of accelerating patient access to promising treatments. For more information, visit www.TD2inc.com

About Deep Lens

Deep Lens is a digital healthcare company focused on a revolutionary approach to accelerate the recruitment of cancer patients best suited to clinical trials. VIPER, Deep Lens’s integrated cloud platform, provides healthcare teams with visibility and workflows that combine lab, EMR and genomic data to match cancer patients with clinical trials and therapies. accuracy at the time of diagnosis, accelerating recruitment and reducing study times to bring the game-changing therapies to market sooner. Growing with sponsors, suppliers and strategic partners, Deep Lens challenges the status quo so that patients can get the best therapies. For more information, visit www.deeplens.ai.

  1. Citeline Trialtrove July 2021

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210916005481/en/

Contacts

Kristen dempsey
Vice President, Marketing
[email protected]
314-920-6252

Source link

About Hector Hedgepeth

Hector Hedgepeth

Check Also

Diadem presents data at 22nd International Alzheimer’s Drug Discovery Conference, emphasizing that his blood biomarker test is 84% ​​concordant with amyloid brain imaging

Further analysis of clinical validation data shows that Diadem’s AlzoSure® prediction is highly concordant with …

Leave a Reply

Your email address will not be published. Required fields are marked *